This phase 2 study tests a new drug called ARX788 in 72 adults with HER2-positive metastatic breast cancer that has spread and is not removable by surgery. Participants must have already been treated with a specific prior therapy (T-DXd) and up to 5 total prior treatments. The ma…
Phase: PHASE2 • Sponsor: Ambrx, Inc. • Aim: Disease control
Last updated May 17, 2026 10:38 UTC